InMed Pharmaceuticals Inc. announced the appointment of Eric Hsu, Ph.D., as Vice President of Preclinical Research and Development. In this capacity, Dr. Hsu will assume primary responsibility for advancing the company's cannabinoid biosynthesis manufacturing process and preclinical research on new drug candidates, including INM-085 for glaucoma and INM-405 for pain. Prior to joining InMed, Dr. Hsu held various positions with enGene Inc., including VP of Research and VP of Scientific Affairs and Operations.